艾司西酞普兰联合脑电生物反馈治疗脑卒中后焦虑障碍的疗效研究

Research on therapy of combining Escitalopram with EEG biofeedback in the treatment of post-stroke anxiety disorder (PSAD)

目的:了解艾司西酞普兰联合脑电生物反馈治疗脑卒中后焦虑障碍的疗效。方法:我院2017年4月~2018年6月60例脑卒中后焦虑障碍患者,随机分为二组各30例,研究组应用脑电生物反馈治疗,每周2次,同时口服艾司西酞普兰片治疗。对照组仅口服艾司西酞普兰片治疗。研究周期共8周。治疗期间禁止应用其它抗抑郁剂。比较两组治疗前后HAMA、SAS指标及治疗效果。结果:研究组治疗总有效率(100%)高于对照组(70%);两组治疗前HAMA、SAS指标比较差异无统计学意义(P>0.05),治疗后各组指标均得到改善,且研究组改善明显,两组比较差异有统计学意义(P<0.05)。结论:艾司西酞普兰联合脑电生物反馈治疗脑卒中后焦虑障碍的疗效确切,可有效改善焦虑症状,且无明显不良反应,安全性好。

Objective: to understand the therapy of combining Escitalopram with EEG biofeedback in the treatment of PSAD. Methods: From April 2017 to June 2018,60 patients with PSAD were randomly divided into two groups,30 in each group. The research group was treated with EEG biofeedback twice a week,while taking Escitalopram tablets. The research period was 8 weeks. Other antidepressants are prohibited during the treatment. The HAMA,SAS indexes and therapy of the two groups were compared before and after the treatment. Results: The total effective rate of the study group (100%) than that of the control group (70%). There was no significant difference in HAMA and SAS between the two groups before the treatment ( P >0.05). After the treatment,the indexes of each group were obviously improved,and the difference was significant in statistics ( P <0.05). Conclusions: Escitalopram combined with EEG biofeedback is effective in the treatment of PSAD,which can effectively improve anxiety symptoms without obvious adverse reaction and has good safety.